ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

  • Post author:
  • Post category:Newsroom

Conference call and webcast on Wednesday, September 18 at 2:30 pm CET/8:30 am EDT

  • TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on plan
  • Immune modulation collaboration entered into with SQZ Biotechnologies
  • Board strengthened with appointment of Dr. Jean Paul Kress as Chairman
  • Cash position of €94.5 million ($107.5 million) at the end of June